Moleculin Biotech (MBRX)
(Delayed Data from NSDQ)
$4.32 USD
-0.14 (-3.14%)
Updated Jun 7, 2024 03:59 PM ET
After-Market: $4.32 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Moleculin Biotech, Inc. [MBRX]
Reports for Purchase
Showing records 141 - 160 ( 162 total )
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Annamycin Accumulates In Lung Models - Potential To Treat Lung Metastases
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Interim Phase 1 Results in AML Demonstrate Highly Favorable Safety - Efficacy
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Positive Preliminary Phase 1 Data in MF-CTCL - Likely Justifies a Phase 2 Trial
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Transfer of Coverage With Buy Rating and $5PT
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Coverage Update - Healthcare Sector
Provider: Roth Capital Partners, Inc.
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
New Pipeline Intersection With Immuno-Oncology
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Unclassified
Healthcare - ORD-ARN-JFK: Crossing Our Onco Radar
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J
Company: Moleculin Biotech, Inc.
Industry: Unclassified
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Moleculin Biotech, Inc.
Industry: Unclassified
Company: Moleculin Biotech, Inc.
Industry: Unclassified
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Moleculin Biotech, Inc.
Industry: Unclassified
Company: Moleculin Biotech, Inc.
Industry: Unclassified
Does Liposomal Therapy in AML Ring a Bell? Initiating with Buy and $8 PT
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J